Digital Medicare advisor Chapter landed $42 million in a Series B funding round led by Addition, with participation from Narya Capital, Susa Ventures, Maverick Ventures, XYZ Venture Capital, Core Innovation Capital and Health2047 Capital Partners.

The company is able to help employers work with their employees on switching their plans to Medicare. Patients can use the platform to navigate the Medicare system. 

As of today, the company has a total of $61 million in funding.  

Clinical prediction software company Quris nabbed $28 million in seed-funding round led by Welltech Ventures, with participation from iAngels and GlenRock Capital. 

The new cash is expected to help expand the team, and help field novel drug R&D efforts. The tool's clinical AI prediction platform is currently working with partners on drug development for Fragile X syndrome (FXS). 

“Now is the time to tap technology to transform drug development and end the costly cycle of failed clinical trials,” Quris CEO Isaac Bentwich said in a statement. “The added investor support will help Quris grow the team and partnerships needed to create a clear view to predict the clinical safety of drugs for individual patients. With the technology advances at our disposal, we can close the clinical prediction gap.”

Maternity-focused digital health company Diana Health scored $11 million in a Series A funding round led by LRVHealth and .406 Ventures, with participation from AlleyCorp. The new funds will be used to help the startup launch its first location.

The company partners with hospitals to bring tech-backed services to patients and clinicians digital resources to personalize the maternity journey.  

“The care we receive as women, particularly during pregnancy and birth, has the potential to impact population health across generations while building lifelong connections between a family and their healthcare provider,” Kate Condliffe, cofounder and CEO of Diana Health, said in a statement.

“Traditional care models can make it challenging for providers to embrace this opportunity. That’s why we are completely restructuring care programs to provide engaging, whole health support that will drive meaningful change in the lives of women and families.”

Boston-based startup PostEra scored $24 million in Series A funding for its machine learning preclinical drug discovery technology. The round was led by Clermont Group with participation from Breyer Capital, Lifeforce Capital and I2BF Global Ventures, as well as existing investors. 

The new funds will go towards helping the company continue to develop its medicinal chemistry platform, as well as team up with other companies and begin its own drug discovery. 

"PostEra has made large strides in demonstrating the real utility of our AI-first medicinal chemistry platform to accelerate small molecule drug discovery," Aaron Morris, CEO of PostEra, said in a statement. "We have a proven record in deploying our machine learning technology to unify the Design-Make-Test cycle of medicinal chemistry and vastly improve upon traditional trial-and-error based approaches."

Senior-focused insurtech company the Helper Bees announced a $12.8 million Series B funding round. Trust Ventures led the round, with participation from Silverton Partners, Northwestern Mutual Fund Ventures, Impact Engine and Congress Avenue Ventures. 

The company is focused on helping seniors age in place. The company works with a person's insurance company to provide data analytics and tech-backed services, as well as streamlined insurance claims. 

Ianacare, a Boston-based startup focused on supporting caregivers, landed $12.1 million in Series A funding, according to TechCrunch.

The service lets caregivers create social circles of friends and family members to help with daily tasks. It helps link users to benefits and local resources, and also provides coaching. 

Digital self-neuromodulation therapy company GrayMatters Health announced a $10 million Series A funding round. Otsuka Medical Devices led the funding round. 

The Israeli company is focused on treating mental health conditions. It uses ECG and fMRI data to create a person's EEP (Electrical Fingerprint) biomarker. The system includes an EEG-neurofeedback device that can help regulate a patient's EFP biomarker, according to its website. 

"GrayMatters is introducing the first digital therapeutic device that directly targets and regulates specific brain biomarkers associated with mental disorders, whereas digitizing existing therapy methods focus on mitigating the resulting symptoms and behaviors," said Oded Kraft, GrayMatters Health cofounder and CEO.

"This funding round will help GrayMatters Health complete its clinical investigation, obtain clearance from regulatory authorities and launch Prism for PTSD in the United States. It also supports our collaboration with McLean Hospital, the largest psychiatric affiliate of Harvard Medical School and a member of Mass General Brigham. Together we plan to conduct a clinical investigation to determine Prism's efficacy and safety as an adjunct treatment for Major Depressive Disorder (MDD) with anhedonia."

Digital clinical trial platform CRIO scored $9 million in Series B funding. Abbhi Capital led the round, with participation from Rally Ventures and NXT Ventures. This new investment round brings the company's total raise to $15.7 million. 

The new infusion of cash will go towards expanding the product, engineering and business-development teams. The Boston-based company works with a number of healthcare stakeholders to help streamline regulatory workflows and capture clinical data.